alexa Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Steroids & Hormonal Science

Author(s): Donnell D, Harrison LI, Ward S, Klinger NM, Ekholm BP,

Abstract Share this page

Abstract The acute safety of the alternative chlorofluorocarbon-free (CFC-free) propellant HFA-134a from a pressurized metered-dose inhaler (MDI) was assessed in 12 healthy male subjects according to a double-blind, randomized, crossover design. On each of three consecutive days, cumulative doses of 1,2,4,8 and 16 inhalations were administered 30 min apart from one of three MDIs. The three MDIs contained either the HFA-134a CFC-free system without drug (HFA-Placebo), the CFC-free system with salbutamol sulphate (HFA-Salbutamol), or a conventional CFC propellant mixture without drug (CFC-Placebo). Pulmonary function (FEV1, FEF25-75\%), cardiovascular performance (heart rate and blood pressure), objective tremor measurements and serum potassium were measured after each incremental dose. Similar responses for pulmonary function, cardiovascular performance, tremor and serum potassium were observed between the HFA-Placebo and CFC-Placebo groups. No statistically significant difference was seen in change from baseline of any parameter between the two propellant systems. The administration of HFA-Salbutamol produced statistically significant dose-related increases in heart rate, systolic blood pressure and tremor and a significant dose-related decrease in serum potassium; these responses were expected based on cumulative doses of active drug. Blood samples for HFA-134a analysis were collected to measure systemic absorption of this propellant. Levels of HFA-134a between 200 and 700 were detected in all subjects given the CFC-free system. This study shows that acute inhalation of HFA-134a in a CFC-free system is as safe as a CFC propellant system. Salbutamol sulphate in the CFC-free system can be delivered in a dose-linear fashion, without any noticeable change in the safety profile of active drug.
This article was published in Eur J Clin Pharmacol and referenced in Journal of Steroids & Hormonal Science

Relevant Expert PPTs

Relevant Speaker PPTs

  • Xavier Guerrero-Pich
    PPT Version | PDF Version
  • Alessandro Pini
    A novel synthetic antimicrobial peptide for the cure of gram-negative infections: Mechanism of action, efficacy in vivo, toxicity, bio-distribution and resistance selection
    PPT Version | PDF Version
  • K Mulkijanyan
    Plant biopolymers from Boraginaceae family species and their synthetic derivatives: Prospective pharmacological agents
    PPT Version | PDF Version
  • Manoj Kumar Chhikara
    How promising is the development of a semi-synthetic meningococcal conjugate vaccine ?
    PDF Version
  • Jianbo Wang
    Transcriptome and small RNA gene expression changes in synthetic allohexaploids of
    PPT Version | PDF Version
  • Werner Lottermoser
    Application of a Difference Electron Nanoscope (DEN): Correlation between 3D Magnetical Structures of Synthetic Fayalite with Synchrotron and Neutron Diffraction and Mössbauer Spectroscopy
    PPT Version | PDF Version
  • Jianping Yu
    Photosynthetic Ethylene Production in a Cyanobacterium
    PDF Version
  • Murad H. Al-Salamat
    Design of small synthetic molecules that mimic IL-4 binding to IL-4Rα, which therefore promotes alternate macrophage differentiation (M2) with minimal effect on the endothelial and vascular IL-4Rα.
    PDF Version

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version